At the AGM, DM told us that the Maximum Tolerated Dose (MTD) has been confirmed, they know the dose limiting toxicities (DLTs), that ZEN-3694 had good pharmacokinetic properties, drug exposures were reaching IC50 cell proliferation values, that they've shown robust target modulation for MYC, BCL2, CCR1, IL1RN, and GPR183, that they've seen an on‐target safety profile and that the longest patient on drug now beyond 4 months (that was back in December).

Recall, they were also considering trying out an intermittent dosing schedule as opposed to every day dosing. DM mentioned that intermittent dosing schedule cohorts may be initiated in Q1/17 for recommended Phase 2 dose. They were still in discussion on this and this could be the reason why we haven't heard anything yet. They may be in the process of determining if intermittent dosing has any advantages/disadvantages over every day dosing. Most, if not all, of the published reports on other pan-BET inhibitors used for oncology indications seem to have resorted to intermittent dosing due to the side effects.

Zenith has a half-hour presentation at the Feb 13-14 BIO CEO & Investor Conference, as does Resverlogix. That's two weeks away. Hopefully we'll get a trial update on or before then. I emailed IR at Resverlogix and Zenith yesterday to find out if they plan to webcast these presentations. No response yet.

The other thing to keep an eye out for is news on the Zenith fast track patent. At the AGM, they described the process as breaking down patent into most important component and you put that through the fast track. DM mentioned that this fast track component should be finalized Q1. The rest of it, the divisional patent, will go normal process and this can take 3 years. DM mentioned that they need to have a published patent to get a licensing deal over the finish line in China. Once you have fast track approved, the follow on patents in subsequent other countries happen very fast. 

BearDownAZ